Insider Selling: InspireMD (NYSE:NSPR) Insider Sells $10,455.18 in Stock

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 3,858 shares of the business’s stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $2.71, for a total value of $10,455.18. Following the sale, the insider owned 1,135,319 shares in the company, valued at approximately $3,076,714.49. The trade was a 0.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shane Thomas Gleason also recently made the following trade(s):

• On Tuesday, May 19th, Shane Thomas Gleason sold 22,778 shares of InspireMD stock. The stock was sold at an average price of $1.01, for a total value of $23,005.78.

InspireMD Stock Down 2.9%

Shares of NSPR opened at $1.00 on Friday. InspireMD, Inc. has a 52 week low of $0.97 and a 52 week high of $2.93. The company has a market capitalization of $46.84 million, a price-to-earnings ratio of -1.33 and a beta of 0.82. The stock’s 50-day moving average price is $1.38 and its 200-day moving average price is $1.66.

Analysts Set New Price Targets

A number of analysts have recently commented on NSPR shares. Maxim Group started coverage on InspireMD in a research note on Monday, February 2nd. They issued a “buy” rating and a $6.00 target price on the stock. Lake Street Capital set a $4.00 target price on InspireMD in a research note on Monday, May 4th. Loop Capital set a $5.00 target price on InspireMD in a research note on Tuesday, February 24th. Finally, Piper Sandler restated an “overweight” rating and issued a $3.00 target price (down from $4.00) on shares of InspireMD in a research note on Tuesday, May 5th. Three analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $4.50.

Key Stories Impacting InspireMD

Here are the key news stories impacting InspireMD this week:

• Positive Sentiment: Wall Street still has a constructive view on InspireMD, with multiple analysts maintaining Buy ratings and a consensus price target well above the current share price. InspireMD (NSPR) Stock Forecast & Price Target
• Neutral Sentiment: The latest insider sale by Shane Thomas Gleason involved 3,858 shares and was disclosed as being related to tax withholding obligations from vested equity awards, which often makes the transaction less meaningful as a trading signal. SEC filing
• Neutral Sentiment: There were several earlier insider sales by the same executive this month and in prior months, but the reported amounts were relatively small and also tied to equity-award tax obligations. SEC filing
• Negative Sentiment: Multiple insider sales can still pressure sentiment because investors may interpret them as limited near-term confidence, especially with NSPR trading near its 52-week low and below key moving averages. SEC filing

Institutional Trading of InspireMD

A number of hedge funds have recently modified their holdings of the stock. XTX Topco Ltd purchased a new position in InspireMD during the fourth quarter worth approximately $30,000. Renaissance Technologies LLC purchased a new position in InspireMD during the first quarter worth approximately $29,000. Virtu Financial LLC purchased a new position in InspireMD during the fourth quarter worth approximately $31,000. Creative Planning purchased a new position in InspireMD during the second quarter worth approximately $44,000. Finally, Uniting Wealth Partners LLC purchased a new position in InspireMD during the third quarter worth approximately $51,000. Hedge funds and other institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.